Novatek International is pleased to announce that Immunity & Cancer Clinical Stage company, IRX Therapeutics has chosen several key regulatory compliant software solutions from our Nova-LIMS Product Suite for use at their NY, USA site: Nova-QMS, Nova-CPM, Nova-Stability, Material Management, Novatek Environmental Monitoring ,Nova-LIMS Material Management , Consumable Inventory, and our Workload Manager.
IRX’s strategic decision to utilize the building block-like components of Novatek’s Product suite reinforces our mandate for organizations in the life sciences industry to build their solution, with the flexibility to grow at their needs and implement at their pace.
We are pleased to welcome IRX Therapeutics to our family of clientele and look forward to supporting their Quality and Data Compliance needs for years to come.
About IRX THERAPEUTICS:
IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor microenvironment, restoring immune function, and activating a coordinated immune response against the tumor. The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine components. Data collected to date indicates that IRX-2 acts to restore and activate multiple immune cell types, including T cells, dendritic cells, and natural killer cells to recognize and destroy tumors. Currently, IRX-2 is being studied in an ongoing phase 2b clinical trial in patients with newly diagnosed stage II, III, and IVA squamous cell carcinoma of the head and neck (SCCHN) (INSPIRE) (clinicaltrials.gov NCT02609386) and in preoperative early stage breast cancer (ESBC) (clinicaltrials.gov NCT02950259).
Visit Novatek at Booth 37 at this year’s PDA/FDA Sept. 24-25, 2018 in Washington, DC to learn more about our Regulatory Compliant Software Solutions.